Article

Amylin and its relation to insulin and lipids in obese children before and after weight loss

Vestische Hospital for Children and Adolescents Datteln, University of Witten/Herdecke, Dr. F. Steiner Str. 5, 45711 Datteln, Germany.
Obesity (Impact Factor: 4.39). 09/2007; 15(8):2006-11. DOI: 10.1038/oby.2007.239
Source: PubMed

ABSTRACT There are limited data concerning the relationships between amylin, weight status, lipids, insulin, and insulin resistance in obese humans. Therefore, the aim was to study these relationships in cross-sectional and longitudinal analyses.
Fasting amylin, insulin, glucose, triglycerides, low-density lipoprotein (LDL)- and high-density lipoprotein (HDL)-cholesterol, and percentage body fat based on skinfold measurements were determined in 37 obese children (median age, 11.5 years) and compared with 16 lean children of the same age and gender. Furthermore, we analyzed the changes of these variables in the obese children after participating in a one-year weight loss intervention program.
Obese children had significantly (p < 0.01) higher amylin, triglycerides, LDL-cholesterol, and insulin levels as compared with the lean children. In multiple linear regression analysis, amylin was significantly (p < 0.05) correlated to insulin and triglycerides, but not to age, gender, pubertal stage, or BMI. Changes of amylin correlated significantly (p < 0.001) to changes of insulin (r = 0.54) and triglycerides (r = 0.49), but not to changes of BMI or percentage body fat. Substantial weight loss in 17 children led to a significant (p < 0.05) decrease of amylin, triglycerides, and insulin, in contrast to the 20 children without substantial weight loss.
Amylin levels were related to insulin concentrations in both cross-sectional and longitudinal analyses, suggesting a relationship between amylin and insulin secretion. Amylin levels were reversibly increased in obesity and related to triglyceride concentrations.

0 Followers
 · 
132 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: To investigate amylin secretion in women with polycystic ovary syndrome (PCOS). Prospective, case-control study. Academic institution. Twenty women with PCOS and 10 with ovulatory cycles who matched for body mass index. An oral glucose tolerance test was performed, and glucose, insulin, and amylin levels were measured at fasting and after glucose ingestion. The area under the curve for insulin, amylin, and glucose was calculated. Ten women with PCOS were treated with metformin and 10 women with rosiglitazone for 6 months. Amylin levels were measured before and after treatment. Fasting amylin levels and amylin response to oral glucose were significantly increased in women with PCOS. At fasting, there was significant positive correlation between insulin and amylin levels both in women with PCOS and control subjects. After glucose ingestion, amylin response correlated with the glucose response in women with PCOS. Amylin levels decreased with metformin but not with rosiglitazone treatment. In women with PCOS, [1] there is increased secretion of amylin, [2] insulin and amylin secretion is coregulated in the fasting state, [3] after glucose ingestion, glucose levels regulate amylin release, and [4] the insulin-sensitizing agent metformin, but not rosiglitazone, reduces amylin secretion.
    Fertility and sterility 04/2009; 94(1):211-5. DOI:10.1016/j.fertnstert.2009.02.086 · 4.59 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Amylin is the major component of pancreatic amyloid, which is implicated in the development of type 2 diabetes. It is costored with insulin in the secretory granules of pancreatic beta-cells and cosecreted with insulin following stimulation with glucose. Here, we investigate the effect of fatty acids (FAs) on amylin expression and secretion by beta-cells and explore the underlying mechanisms. Palmitate and oleate dose-dependently induced amylin mRNA accumulation in murine pancreatic beta-cell line MIN6 and primary pancreatic islets. the inductive effect of FAs on amylin expression is independent of glucose concentration. FAs upregulated amylin expression at the transcriptional level, and FAs must be metabolized to induce amylin expression. FAs also significantly induced human amylin promoter activation. Pretreatment of MIN6 cells with Ca(2+) chelator (EGTA, BAPTA-AM) PKC inhibitor Gö-6976 or protein synthesis inhibitor cycloheximide significantly inhibited FA-induced amylin mRNA expression. Transcription factors cAMP-responsive element-binding protein, pancreatic and duodenal homeobox factor-1, and peroxisome proliferator-activated receptor were not involved in FA-induced amylin expression. Palmitate and oleate both increased amylin and insulin release from MIN6 cells and stimulated amylin expression but had no effect on insulin expression. Mice refed with Intralipid had significantly higher levels of plasma FFA, amylin, and insulin than those refed with saline. These data demonstrate that FAs differently regulate amylin and insulin expression and induce both amylin and insulin release. Ca(2+) and PKC signaling pathways and de novo-synthesized protein(s) were involved in FA-induced amylin expression. Induction of amylin production and release by FA may contribute to its biological functions under physiological conditions.
    AJP Endocrinology and Metabolism 10/2009; 298(1):E99-E107. DOI:10.1152/ajpendo.00242.2009 · 4.09 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Obesity is a growing health concern in humans and companion animals. Obesity is highly associated with various endocrine abnormalities that are characterized by hormonal imbalance and/or resistance. Weight reduction generally normalizes these endocrine alterations, implicating obesity as a direct cause. Most data in this area have been derived from obese humans, with little data pertaining to hormonal changes in obese dogs and cats. Because the literature contains inconsistent results and because considerable hormone-hormone interactions occur, we have a limited understanding of the obesity-induced changes on the endocrine system in dogs and cats.
    Veterinary Clinics of North America Small Animal Practice 03/2010; 40(2):205-19. DOI:10.1016/j.cvsm.2009.10.004 · 1.04 Impact Factor
Show more

Preview

Download
0 Downloads